Heart failure (HF) has a poor prognosis, and its management is suboptimal, necessitating new therapeutic options for its treatment and management.

In patients with type 2 diabetes, HF is one of the most frequent cardiovascular (CV) complications.

The sodium-glucose cotransporter-2 inhibitor (SGLT-2i) class of antidiabetic drugs has shown beneficial effects on CV outcomes, including HF.

Specifically, the SGLT-2is dapagliflozin and empagliflozin have been demonstrated to be effective for the treatment and prevention of HF with reduced ejection fraction.

Additional evidence from clinical studies may lead to further integration of SGLT-2is into a standard-of-care regimen for the treatment and management of HF.